Seeking Alpha

Stifel Nicolaus ups its target from $8 to $11 on Santarus (SNTS +5%) on the back of its highly...

Stifel Nicolaus ups its target from $8 to $11 on Santarus (SNTS +5%) on the back of its highly successful Phase 3 results for Rifamycin SV MMX in traveler’s diarrhea, and it's successful appeal against Par Pharmaceuticals (PRX). The firm thinks that Zegerid will gain an extra $35M-$45M in annual sales as a result of the court decision, and it maintains a Buy rating on the stock.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)